This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
• This presentation represents the personal views of the speakers and is not intended to represent Sanofi U.S.’ position or legal advice or those of EBG.
• You are excited! You start your new job today. You are working for a new pharmaceutical manufacturer as the Director of Government Pricing and Contracts.
• You have heard about the company’s new drug and you know it will be a blockbuster.
• But wait, your company wants to sell its product to the Department of Veterans Affairs (VA).
• OBRA ‘90 created the Medicaid Drug Rebate Program that required manufacturers to pay rebates to the states based upon pricing calculations.
• Previously, the VA had received high discounts on the pharmaceuticals that it purchased.
• Because these discounts were included in the Medicaid Rebate calculations, manufacturers discontinued the VA prices, causing the VA to cut back on healthcare coverage and programs.
• The Veterans Health Care Act of 1992 “fixed” the problem by imposing pricing calculations and requirements for vendors, including pharmaceutical manufacturers:
– Master Agreement (MA)
– Pharmaceutical Pricing Agreement (PPA)
– FSS Contract
• Participation in the VA FSS for covered drugs is required if the manufacturer wants to participate in Medicaid.
• This means the new company needs to become a government contractor. As a government contractor, the company will be subject to additional obligations and prohibitions.
• There are serious potential sanctions for non-compliance.
• A manufacturer of covered drugs must enter into a MA under which the manufacturer must make available each of its covered drugs on the FSS (38 U.S.C. § 8126(a)(1)).
• The MA outlines the vendor’s responsibilities & obligations associated with the statute. Specifically, the MA requires them to submit non–FAMP data to the VA to establish federal ceiling prices (FCP).
• The terms and conditions of the MA are non–negotiable and the same for all 65 I B contractors. The MA is an evergreen document and, as such, does not expire.
• The manufacturer must also enter into a PPA and agree to sell to the Big Four purchasers through the FSS or a depot at not more than the FCP (38 U.S.C. § 8126(a)(2)).
– VA, DoD, Coast Guard, and the Public Health Service (including Indian Health Services).
• The PPA Addendum A is updated annually to reflect FCPs of covered drugs for the calendar year.
• PPA Addendum A is available at: http://www.va.gov/oal/docs/business/nac/fssPL102-585_2014PpaAddendumA.docx
• To begin the process and obtain the initial MA, PPA, and Interim Agreement (IA) documents, send an initial request to: [email protected]
• Analyze products to determine which are covered drugs (38
U.S.C. § 8126(h)(2)).
– Single Source Drugs means a covered drug which is produced
or distributed under an original NDA approved by the FDA,
including a drug product marketed by any cross-licensed
producers or distributors operating under the NDA (42 U.S.C. §
1396r-8(k)(7)(A)(iv)).
Covered Drugs
Challenges/Points to Remember Review VA guidance for specific questions on certain products (e.g., radiopharmaceuticals), including Dear Manufacturer Letters.
What is a Covered Drug? – Innovator Multiple Source Drugs means a drug that was
originally marketed under an original new drug application (NDA) approved by the Food & Drug Administration (FDA) (42 U.S.C. § 1396r-8(k)(7)(A)(ii)).
– Biologics (means any virus, therapeutic serum, toxin, antitoxin, or analogous product applicable to the prevention, treatment or cure of diseases or injuries of man (any biological products identified under 21 C.F.R. § 600.3).
Covered Drugs
Stakeholders/Sources - Manufacturing - Legal
Est. time frame 4-8 weeks
Challenges/Points to Remember The onus is on the manufacturer . VA considers a manufacturer’s research and arguments, but does not conduct its own research.
• Covered drugs are identified as a single form dosage unit of the drug.
• The single form dose must be identified by the NDC-11.
• Manufacturers must specify each package unit utilized for each covered drug as part of the submission of its reporting data.
• The manufacturer must submit separate non-Federal Average Manufacturer Price (non-FAMP) data and establish an FCP on each package unit of a covered drug.
– Justification for pricing where the VA is not receiving the best price
– Deviations and frequency of deviations in pricing policy
– Country of origin
CSP Analysis
Challenges/Points to Remember
– Contractor must update disclosure for any changes to proposed price lists, discounts, or discounting policies which occur after the submission of the offer, but prior to the close of negotiations.
• Communication – Stakeholders must provide timely and reliable internal communications. – Company needs to have open communication with VA contracting officer.
• Accountability – Ensure various individuals are held accountable for monitoring or sharing
appropriate information. – The contract is a company-wide contract, not a department-centric
contract.
• Tracking – Develop policies, procedure and protocols to track prices, product
additions, deletions and tracking customers to ensure timely updates to contract.
– Maintain a central location for all documents provided to or correspondence with the government regarding the FSS contract.
• Now, you have completed negotiations with the VA and have handled a pre-award audit.
• You know the obligations of maintaining the FSS contract and have kept the hot button issues in mind as you communicate and coordinate with the Contracting Officer.